Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126767
Filing Date
2024-11-14
Accepted
2024-11-14 08:30:40
Documents
76
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-20240930.htm   iXBRL 10-Q 2362909
2 EX-31.1 cadl-ex31_1.htm EX-31.1 15130
3 EX-31.2 cadl-ex31_2.htm EX-31.2 15142
4 EX-32.1 cadl-ex32_1.htm EX-32.1 8436
5 EX-32.2 cadl-ex32_2.htm EX-32.2 8833
  Complete submission text file 0000950170-24-126767.txt   7905198

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20240930.xsd EX-101.SCH 1090977
79 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20240930_htm.xml XML 1056877
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 241457384
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)